Somerville, Mass.-based Mass General Brigham and Boston-based Dana-Farber Cancer Institute will work together to ensure workforce stability as the two organizations navigate the end of a longtime partnership, according to a March 10 report from The Boston Globe.
In April, Boston-based Brigham and Women’s Hospital announced it would phase out all currently contracted Dana-Farber Cancer Institute physician assistants by the end of 2026.
According to the Globe, the organizations recently sent a joint email to staff that said, “Brigham and Women’s Hospital has agreed to rescind the previously issued notice while our organizations engage in further discussions.”
The organizations told the Globe they were working together to “manage a multifaceted transition over the next approximately two and a half years.”
In 2023, Dana-Farber announced it would be ending its longtime partnership with Brigham in 2028 and was planning to construct a freestanding inpatient cancer hospital with Boston-based Beth Israel Deaconess Medical Center. Since the 2023 announcement, Dana-Farber and Beth Israel received approval from the city to develop the cancer hospital, estimated to cost $1.68 billion.
Meanwhile, Mass General Brigham — Brigham’s corporate parent — established the Mass General Brigham Cancer Institute and unveiled plans to invest $400 million to expand oncology services.
Both health systems shared news of significant philanthropic gifts on Feb. 4, with Dana-Farber receiving the largest single gift in the institute’s history and Mass General Hospital receiving $35 million to fund two cancer-focused facilities within the Phillip and Susan Ragon Building, currently under construction.
